Hypophosphatemic rickets linked to the X (XLH) chromosome - KRN 23 (burosumab) therapy: wxpert opinion of the Society for Metabolic Bone Diseases within the Czech Medical Association of J. E. Purkyně

Abstract

Scientific guidance to the incidence, prevalence a treatment options of X-linked hypophosphatemic rickets. Guidelines for burosumab treatment - indications, adverse effects, profit and improvement of the quality of life.

Keywords

• Hypophosphatemic rickets
• burosumab